FDA Releases Safety Alert on Amputation Risk From Diabetes Drug

In a new safety alert, the FDA is warning of a dangerous risk of leg and foot amputations stemming from canagliflozin, the active ingredient in both Invokamet and Invokana, two widely used diabetes drugs. The FDA released the safety alert after reviewing the final results from two different clinical trials that looked at the drugs and their long-lasting effects over a large sample of patients suffering from type 2 diabetes.

For more information on the FDA's safety alert and the symptoms commonly found in diabetes patients who have taken Invokamet or Invokana, please review our case page on Invokamet and Inovokana and contact us immediately at (888) 725-2477 for a free case review.